The Eighth International Mdm2 Workshop
第八届国际Mdm2研讨会
基本信息
- 批准号:9022188
- 负责人:
- 金额:$ 0.78万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-09-22 至 2016-08-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAntineoplastic AgentsAreaAwardBasic ScienceBindingBiologyCancer CenterCitiesCollaborationsCommunitiesComplementDevelopmentDoctor of MedicineDoctor of PhilosophyEducational workshopEmbryonic DevelopmentEnsureEuropeEventFundingFutureGene AmplificationHumanIndividualInternationalLouisianaMDM2 geneMalignant NeoplasmsMedical StudentsMentorsMinorityMissense MutationNew YorkPathway interactionsPlayProtein p53Public HealthReagentRecruitment ActivityReportingResearchResearch PersonnelRoleScientistSenior ScientistSiteStagingStudentsTP53 geneTimeTranslational ResearchTravelTumor Suppressor ProteinsUnderrepresented MinorityUnited KingdomUnited StatesUniversitiesWomanWritingabstractingcareercollegedrug discoverygraduate studentin vivoinhibitor/antagonistinterdisciplinary approachmedical schoolsmeetingsmembermouse modelnoveloverexpressionposterspublic health relevancesocialsymposiumtumorubiquitin-protein ligase
项目摘要
DESCRIPTION (provided by applicant): Project Summary/Abstract The p53 protein has been well characterized as playing a tumor suppressor role in human cancer. Indeed, a majority of human tumors have sustained missense mutation in the TP53 gene. Mdm2 is a major negative regulator of p53 that has been shown to act by inhibiting the transcriptional activity of p53 via direct binding as well as serving as an E3 ubiquitin ligase to target p53 for degradation. Consistent with such findings, Mdm2 has been demonstrated as also playing a role in human tumors with its overexpression or gene amplification being observed in a variety of cancers. The scientific need for the 8th International MDM2 Workshop arises from the central role that the p53 tumor suppressor and its negative regulator Mdm2 have regarding the development and progression of human cancer and the promise that the p53-Mdm2 interaction holds for development of novel therapies. The expansion of the scientific community studying Mdm2 and the need to pursue this area of research with a collaborative multidisciplinary approach has further made it necessary to have Mdm2 Workshops. Thus, while both the p53 and Mdm2 Workshops started as small gatherings of researchers in the field, they have become necessary for future progress. A p53 Workshop is held every two years to bring together the p53 field in order to report on the latest research and to facilitate collaboration and exchange of reagents. The first p53 Workshop was held in 1983 in the United Kingdom. Fourteen years ago, the first complementing Mdm2 Workshop was held in alternating years with the p53 conference. The Workshops have since been held every two years, alternating between Europe and the United States. The 8th International MDM2 Workshop will be held at Tulane University School of Medicine on November 1-4th, 2015. The meeting is being co-organized by Hua Lu (Tulane University) and Wei Gu (Columbia University). The site of the conference is in the Bowers Auditorium, 1555 Poydras Street, New Orleans, Louisiana. Tulane University is a major long-term leasee of the 1555 Poydras building. This Auditorium hosts research seminars and medical student classes for the Tulane Community. Therefore, we are applying for the R13 fund to support this highest level and exciting international meeting in this field, which would dramatically re-energize the research and promote scientific interactions and exchanges in the area.
描述(由申请人提供):项目摘要/摘要p53蛋白已被很好地表征为在人类癌症中发挥肿瘤抑制作用。事实上,大多数人类肿瘤在TP 53基因中具有持续的错义突变。Mdm 2是p53的主要负调节因子,其已被证明通过直接结合抑制p53的转录活性以及作为E3泛素连接酶靶向p53进行降解来起作用。与这些发现一致,Mdm 2已被证明在人类肿瘤中也起作用,在多种癌症中观察到其过表达或基因扩增。第八届国际MDM 2研讨会的科学需求源于p53肿瘤抑制因子及其负调节因子MDM 2在人类癌症发展和进展中的核心作用,以及p53-MDM 2相互作用对开发新疗法的承诺。研究Mdm 2的科学界的扩大以及以多学科协作方法进行这一研究领域的需要进一步使得有必要举办Mdm 2研讨会。因此,虽然p53和Mdm 2研讨会都是作为该领域研究人员的小型聚会开始的,但它们已经成为未来发展的必要条件。每两年举办一次p53研讨会,汇集p53领域的最新研究报告,促进试剂的合作和交流。第一次p53研讨会于1983年在英国举行。14年前,第一次补充Mdm 2研讨会与p53会议隔年举行。此后,讲习班每两年举办一次,在欧洲和美国轮流举办。第八届国际MDM 2研讨会将于2015年11月1日至4日在杜兰大学医学院举行。这次会议由Hua Lu(杜兰大学)和Wei Gu(哥伦比亚大学)共同组织。会议地点在路易斯安那州新奥尔良市波伊德拉斯街1555号鲍尔斯礼堂。杜兰大学是1555年Poydras大楼的主要长期承租人。这个礼堂为杜兰社区举办研究研讨会和医学生课程。因此,我们正在申请R13基金,以支持这一领域最高级别和令人兴奋的国际会议,这将大大重振研究,促进该领域的科学互动和交流。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Hua Lu其他文献
Hua Lu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Hua Lu', 18)}}的其他基金
Validating p53 Ser46 crotonylation as a potential target for possible anti-cancer therapy
验证 p53 Ser46 巴豆酰化作为可能的抗癌治疗的潜在靶点
- 批准号:
10492834 - 财政年份:2022
- 资助金额:
$ 0.78万 - 项目类别:
Validating p53 Ser46 crotonylation as a potential target for possible anti-cancer therapy
验证 p53 Ser46 巴豆酰化作为可能的抗癌治疗的潜在靶点
- 批准号:
10671541 - 财政年份:2022
- 资助金额:
$ 0.78万 - 项目类别:
Digital Nanoplasmonic Quantification of Tumor-derived Extracellular Vesicles in Plasma Microsamples
血浆微样品中肿瘤源性细胞外囊泡的数字纳米等离子体定量
- 批准号:
10037327 - 财政年份:2020
- 资助金额:
$ 0.78万 - 项目类别:
The Role of p53-R249S’s GOF in HCC development
p53-R249S GOF 在 HCC 发展中的作用
- 批准号:
10317044 - 财政年份:2019
- 资助金额:
$ 0.78万 - 项目类别:
Role of the AMPK-MDMX-p53 pathway in cancer
AMPK-MDMX-p53 通路在癌症中的作用
- 批准号:
9753938 - 财政年份:2019
- 资助金额:
$ 0.78万 - 项目类别:
The Role of p53-R249S’s GOF in HCC development
p53-R249S GOF 在 HCC 发展中的作用
- 批准号:
10543734 - 财政年份:2019
- 资助金额:
$ 0.78万 - 项目类别:
Targeting GRP78 for p53 activation as anti-cancer therapy
靶向 GRP78 激活 p53 作为抗癌疗法
- 批准号:
9008031 - 财政年份:2015
- 资助金额:
$ 0.78万 - 项目类别:
Dual Targeting of the p53 pathway for development of anti-cancer therapy
双重靶向 p53 通路以开发抗癌疗法
- 批准号:
9102015 - 财政年份:2012
- 资助金额:
$ 0.78万 - 项目类别:
Dual Targeting of the p53 pathway for development of anti-cancer therapy
双重靶向 p53 通路以开发抗癌疗法
- 批准号:
8551655 - 财政年份:2012
- 资助金额:
$ 0.78万 - 项目类别:
Dual Targeting of the p53 pathway for development of anti-cancer therapy
双重靶向 p53 通路以开发抗癌疗法
- 批准号:
8421099 - 财政年份:2012
- 资助金额:
$ 0.78万 - 项目类别:
相似海外基金
Delays in Acquisition of Oral Antineoplastic Agents
口服抗肿瘤药物的获取延迟
- 批准号:
9975367 - 财政年份:2020
- 资助金额:
$ 0.78万 - 项目类别:
Eliminate the difficulty of venous puncture in patients receiving antineoplastic agents - Development of a new strategy for the prevention of induration-
消除接受抗肿瘤药物的患者静脉穿刺的困难 - 制定预防硬结的新策略 -
- 批准号:
16K11932 - 财政年份:2016
- 资助金额:
$ 0.78万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Molecular mechanisms of the antineoplastic agents inhibiting DNA replication and their applications to cancer patient treatmen
抗肿瘤药物抑制DNA复制的分子机制及其在癌症患者治疗中的应用
- 批准号:
19591274 - 财政年份:2007
- 资助金额:
$ 0.78万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
PNET EXPERIMENTAL THERAPEUTICS--ANTINEOPLASTIC AGENTS AND TREATMENT DELIVERY
PNET 实验治疗——抗肿瘤药物和治疗实施
- 批准号:
6346309 - 财政年份:2000
- 资助金额:
$ 0.78万 - 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
- 批准号:
2885074 - 财政年份:1999
- 资助金额:
$ 0.78万 - 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
- 批准号:
6174221 - 财政年份:1999
- 资助金额:
$ 0.78万 - 项目类别: